Evidence map›Paper›PMID 21139020›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2011

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).

C Le Péchoux, A Laplanche, C Faivre-Finn, T Ciuleanu, R Wanders, D Lerouge, R Keus, M Hatton, G M Videtic, S Senan and 6 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00005062 (A Phase III Trial Comparing High Versus Standard Dose of Prophylactic Cranial Irradiation), which is not on this map. Cited by 80 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 6 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00005062 phase3completednot on this map

A Phase III Trial Comparing High Versus Standard Dose of Prophylactic Cranial Irradiation (PCI) in Limited Small Cell Lung Cancer Complete Responders

TypeinterventionalSponsorGustave Roussy, Cancer Campus, Grand ParisRan1999 to 2005ConditionsLung CancerArmsradiation therapy
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 6 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2021
    Guideline
  3. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of oncology : official journal of the European Society for Medical Oncology · 2021
    Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 7 countries.

C Le PéchouxRadiation Oncology Department. Electronic address: lepechoux@igr.fr.
A LaplancheBiostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif, France.
C Faivre-FinnDepartment of Clinical Oncology, The Christie, Manchester, UK.
T CiuleanuMedical Oncology Department, Institutul Oncologic I. Chiricuta, Cluj-Napoca, Romania.
R WandersRadiation Oncology Department, MAASTRO Clinic, Maastricht, The Netherlands.
D LerougeRadiation Oncology Department, Centre François Baclesse, Caen, France.
R KeusRadiation Oncology Department, Arnhem's Radiotherapeutisch Instituut, Arnhem, The Netherlands.
M HattonDepartment of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
G M VideticRadiation Oncology Department, Cleveland Clinic Foundation, Cleveland, USA.
S SenanRadiation Oncology Department, VU University Medical Centre, Amsterdam, The Netherlands.
A WolfsonRadiation Oncology Department, University of Miami School of Medicine, Miami, USA.
R JonesDepartment of Clinical Oncology, Beatson Oncology Centre, Glasgow, UK.
R ArriagadaRadiation Oncology Department, Karolinska Institutet, Stockholm, Sweden.
E QuoixDepartment of Pneumology, Hôpital Lyautey, Strasbourg, France.
A DunantBiostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif, France.
Prophylactic Cranial Irradiation (PCI) Collaborative Group
Institut Gustave Roussy · FRAmsterdam UMC Location Vrije Universiteit Amsterdam · NLBeatson West of Scotland Cancer Centre · GBCentre François Baclesse · FRCleveland Clinic · USInpex (Japan) · JPInstitute of Oncology Prof. Dr. Ion Chiricuta · ROKarolinska Institutet · SEMaastro Clinic · NLRadiotherapiegroep · NLUniversity of Miami · USWeston Park Cancer Centre · GB

Funding

EORTC HEADQUARTERSU10CA011488 · NCI · EUROPEAN ORG/RES/TREATMENT/CANCER · PI LACOMBE, DENIS · 1985 to 2015
$6.6M
NCI NIH HHS 5U10 CA11488-30NCI NIH HHS 5U10 CA11488-31NCI NIH HHS 5U10 CA11488-32NCI NIH HHS 5U10 CA11488-33NCI NIH HHS 5U10 CA11488-34NCI NIH HHS 5U10 CA11488-35NCI NIH HHS 5U10 CA11488-36NCI NIH HHS 5U10 CA11488-37NCI NIH HHS 5U10 CA11488-38NCI NIH HHS U10 CA011488
6 · The paper itself

Abstract

backgroundWe recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL). PATIENTS AND

methodsAt predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC-Radiation Therapy Oncology Group Late Effects Normal Tissue-Subjective, Objective, Management, Analytic scale was used for clinicians' assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose.

resultsOver the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P < 0.005).

conclusionPatients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.

Indexed as

Quality of LifeSurveys and QuestionnairesBrainBrain NeoplasmsCognition DisordersCranial IrradiationFollow-Up StudiesHumansLogistic ModelsLung NeoplasmsMemory DisordersMood DisordersNeuropsychological TestsSmall Cell Lung CarcinomaTreatment Outcome

Identifiers

PMID21139020
PMCPMC3082159
OpenAlexW2129784835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.